Heart failure patients get better meds in special clinic
NCT ID NCT06700213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a special clinic (GDMT Clinic) helps heart failure patients get the right medications compared to usual care. About 300 adults with heart failure took part over 12 weeks. The clinic aimed to improve medication use, health status, and heart function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
300 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Ambulatory patients with NYHA Class I-IV HF, aged ≥18 years, directly referred to GDMT Clinic from cardiology clinics at MGH. A minimum of 75 patients with HFrEF will be included in the GDMT Clinic arm. Patients with improved EF will be included as HFrEF.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of HF, including new onset disease * Established cardiovascular follow up at MGH * Receiving sub-optimal medical care defined as \<50% target doses of GDMT agents * Age ≥18 years * For HFpEF: * Presence of structural heart disease (LAVi \>34 mL/Kg2, E/e' \>14, or LVH) * Recent HF hospitalization or historical NT-proBNP \>300 pg/mL Exclusion Criteria: * Planned referral to the Advanced HF program * Decompensated HF * End-stage kidney disease * eGFR \<15 mL/min/1.73m2 or on renal replacement therapy * Untreated severe valvular heart disease * Advanced HF * Inotropic support * Transplant or MCS planned * Enrolled in hospice or palliative care * Life expectancy \<12 months due to non-CV disease * Pericardial constriction * Hypertrophic cardiomyopathy * Unwillingness or inability to take GDMT * Pregnancy or breast feeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?
- Can modern heart failure drugs reverse damage in three months?